One-Year combo pill strategy aims to improve CLL/SLL outcomes

NCT ID NCT06520098

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 24 times

Summary

This study is for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). It compares staying on the BTKi pill alone versus adding a second pill, venetoclax, for one year and then stopping both. The goal is to see if the combination leads to a better response and less fatigue. About 100 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Durham VA Medical Center, Durham, NC

    RECRUITING

    Durham, North Carolina, 27705-3875, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Kansas City VA Medical Center, Kansas City, MO

    RECRUITING

    Kansas City, Missouri, 64128-2226, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • San Francisco VA Medical Center, San Francisco, CA

    RECRUITING

    San Francisco, California, 94121-1563, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    RECRUITING

    Seattle, Washington, 98108-1532, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.